NO2023013I1 - Combination of foslevodopa and foscarbidopa, each in all forms protected by the basic patent - Google Patents

Combination of foslevodopa and foscarbidopa, each in all forms protected by the basic patent

Info

Publication number
NO2023013I1
NO2023013I1 NO2023013C NO2023013C NO2023013I1 NO 2023013 I1 NO2023013 I1 NO 2023013I1 NO 2023013 C NO2023013 C NO 2023013C NO 2023013 C NO2023013 C NO 2023013C NO 2023013 I1 NO2023013 I1 NO 2023013I1
Authority
NO
Norway
Prior art keywords
foslevodopa
foscarbidopa
combination
basic patent
forms protected
Prior art date
Application number
NO2023013C
Other languages
English (en)
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54478240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2023013(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of NO2023013I1 publication Critical patent/NO2023013I1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/24—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/094—Esters of phosphoric acids with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO2023013C 2014-10-21 2023-03-20 Combination of foslevodopa and foscarbidopa, each in all forms protected by the basic patent NO2023013I1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462066771P 2014-10-21 2014-10-21
PCT/US2015/056686 WO2016065019A1 (en) 2014-10-21 2015-10-21 Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease

Publications (1)

Publication Number Publication Date
NO2023013I1 true NO2023013I1 (no) 2023-03-20

Family

ID=54478240

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2023013C NO2023013I1 (no) 2014-10-21 2023-03-20 Combination of foslevodopa and foscarbidopa, each in all forms protected by the basic patent

Country Status (35)

Country Link
US (7) US9446059B2 (no)
EP (3) EP3569587A1 (no)
JP (5) JP6567049B2 (no)
KR (2) KR20230066484A (no)
CN (4) CN107206013A (no)
AR (1) AR102389A1 (no)
AU (3) AU2015335941B2 (no)
BR (1) BR112017008198B1 (no)
CA (1) CA2965379A1 (no)
CY (1) CY1121826T1 (no)
DK (1) DK3209302T3 (no)
ES (1) ES2739536T3 (no)
FI (1) FIC20230014I1 (no)
FR (1) FR23C1035I1 (no)
HR (1) HRP20191285T1 (no)
HU (2) HUE044115T2 (no)
IL (3) IL251829B (no)
LT (2) LT3209302T (no)
MX (2) MX2021003840A (no)
MY (1) MY189519A (no)
NL (1) NL301224I2 (no)
NO (1) NO2023013I1 (no)
PH (1) PH12017500746B1 (no)
PL (1) PL3209302T3 (no)
PT (1) PT3209302T (no)
RS (1) RS58972B1 (no)
RU (2) RU2743347C2 (no)
SA (1) SA521421115B1 (no)
SG (1) SG11201703170RA (no)
SI (1) SI3209302T1 (no)
TR (1) TR201908296T4 (no)
TW (2) TWI755257B (no)
UA (1) UA120437C2 (no)
WO (1) WO2016065019A1 (no)
ZA (1) ZA201702760B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
HRP20231716T1 (hr) 2014-03-13 2024-03-15 Neuroderm Ltd. Pripravci inhibitora dopa dekarboksilaze
RU2743347C2 (ru) * 2014-10-21 2021-02-17 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
EP4295909A2 (en) * 2016-04-20 2023-12-27 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
US11148999B2 (en) 2016-06-22 2021-10-19 MedChem Partners, LLC Nitric oxide donors
WO2018154447A1 (en) * 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US20180311238A1 (en) * 2017-04-28 2018-11-01 Saniona A/S Selective Agonist Of a6 Containing nAChRs
WO2019097120A1 (en) 2017-11-16 2019-05-23 Orion Corporation New use and pharmaceutical dosage forms
MA50800A (fr) 2017-11-24 2020-09-30 H Lundbeck As Nouveaux promédicaments de catécholamine destinés à être utilisés dans le traitement de la maladie de parkinson
CN110294789A (zh) * 2018-03-21 2019-10-01 海南大学 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用
WO2020102628A1 (en) 2018-11-15 2020-05-22 Abbvie Inc. Pharmaceutical formulations for subcutaneous administration
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
CN113727974A (zh) 2019-05-21 2021-11-30 H.隆德贝克有限公司 用于治疗帕金森病的新儿茶酚胺前药
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
EP4223288B1 (en) 2022-02-07 2024-03-06 Berlirem GmbH Novel kit of pharmaceutical preparations for the treatment of parkinson's disease

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) * 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US4016288A (en) * 1975-08-13 1977-04-05 Merck & Co., Inc. Compositions and method of treating hypertension
DD230865B1 (de) * 1982-08-09 1987-05-20 Dresden Arzneimittel Verfahren zur herstellung von hydrazinocarbonsaeurederivaten durch n-aminierung von aminocarbonsaeurederivaten
US4508706A (en) * 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
US4618484A (en) 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
IT1213182B (it) * 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
US4616484A (en) 1984-11-30 1986-10-14 Kysor Industrial Corporation Vehicle refrigerant heating and cooling system
IT1200427B (it) 1985-03-22 1989-01-18 Afros Spa Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
JPH02138A (ja) 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd Ｌ‐ドーパ誘導体
IT1226727B (it) 1988-07-29 1991-02-05 Simes Farmaci precursori della dopamina.
DE69016688T2 (de) * 1989-04-20 1995-10-05 Zambon Spa Dopamin-Medikament-Vorstufe.
GB9102812D0 (en) 1991-02-11 1991-03-27 Enzymatix Ltd Compounds
IT1255471B (it) 1992-07-30 1995-11-02 Zambon Spa Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono
SE9203594D0 (sv) 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US6576766B1 (en) * 1997-11-12 2003-06-10 Ariad Pharmaceuticals, Inc. Signal transduction inhibitors, compositions containing them
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
KR20050016449A (ko) * 2002-05-29 2005-02-21 임팩스 라보라토리즈, 인코포레이티드 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형
JPWO2004000863A1 (ja) 2002-06-20 2005-10-20 日本水産株式会社 プロドラッグ、その医薬としての使用、およびその製法
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
WO2004069146A2 (en) 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
EP1670450B8 (en) 2003-08-29 2011-03-23 Centocor Ortho Biotech Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
ES2360759T3 (es) * 2003-08-29 2011-06-08 Centocor Ortho Biotech Inc. Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
KR20060109922A (ko) 2003-10-31 2006-10-23 알자 코포레이션 가바펜틴 및 프리가발린의 개선된 흡수를 위한 조성물 및제형
JP4781352B2 (ja) * 2004-06-04 2011-09-28 ゼノポート，インコーポレーテッド レボドパプロドラッグおよびその組成物ならびにその使用
WO2006014282A2 (en) 2004-07-06 2006-02-09 Abbott Laboratories Prodrugs of hiv protease inhibitors
US7563821B2 (en) * 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
EP2063865A1 (en) * 2006-05-31 2009-06-03 Solvay Pharmaceuticals GmbH Long term 24 hour intestinal administration of levodopa/carbidopa
WO2007144422A2 (en) * 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and l-dopa
US7709527B2 (en) 2006-12-21 2010-05-04 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
GB0713189D0 (en) 2007-07-06 2007-08-15 Proximagen Ltd Amino acid derivatives
EP2252284B1 (en) * 2008-02-06 2011-05-25 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
JP5757864B2 (ja) 2008-05-20 2015-08-05 ニューロジェシックス， インコーポレイテッド 水溶性アセトアミノフェン類似体
US20130253056A1 (en) 2009-05-19 2013-09-26 Neuroderm, Ltd. Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same
LT2432454T (lt) 2009-05-19 2017-07-10 Neuroderm Ltd Kompozicijos, skirtos nepertraukiamam dopa dekarboksilazės inhibitorių vartojimui
NZ601747A (en) 2009-11-09 2014-08-29 Xenoport Inc Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
US8937151B2 (en) 2010-03-04 2015-01-20 University Of Notre Dame Du Lac Gelatinase inhibitors and prodrugs
NZ610911A (en) 2010-11-15 2015-02-27 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
JP5423905B2 (ja) 2010-12-02 2014-02-19 小野薬品工業株式会社 新規化合物及びその医薬用途
WO2012079072A2 (en) 2010-12-10 2012-06-14 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
US8765189B2 (en) * 2011-05-13 2014-07-01 Howmedica Osteonic Corp. Organophosphorous and multivalent metal compound compositions and methods
HRP20211442T1 (hr) 2013-03-13 2022-02-04 Neuroderm Ltd Kombinacija za liječenje parkinsonove bolesti
CA3212170A1 (en) 2013-03-15 2014-09-18 Techfields Pharma Co., Ltd. Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases
RU2743347C2 (ru) 2014-10-21 2021-02-17 Эббви Инк. Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
EP4295909A2 (en) 2016-04-20 2023-12-27 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
EP3518920A1 (en) 2016-09-29 2019-08-07 Berlirem GmbH L-dopa derivatives for the treatment of neurological diseases
WO2018154447A1 (en) 2017-02-21 2018-08-30 Neuroderm Ltd Dopa decarboxylase inhibitor compositions

Also Published As

Publication number Publication date
LTPA2023519I1 (no) 2023-06-26
IL268885B (en) 2020-08-31
AU2015335941A1 (en) 2017-05-04
CY1121826T1 (el) 2020-07-31
RU2021103000A (ru) 2021-03-01
MX2017005236A (es) 2017-07-26
US20160106765A1 (en) 2016-04-21
HRP20191285T1 (hr) 2019-10-18
LT3209302T (lt) 2019-06-10
JP6567049B2 (ja) 2019-08-28
KR20170071599A (ko) 2017-06-23
CN111454290A (zh) 2020-07-28
IL251829A0 (en) 2017-06-29
FIC20230014I1 (fi) 2023-03-31
JP6932227B2 (ja) 2021-09-08
KR20230066484A (ko) 2023-05-15
CA2965379A1 (en) 2016-04-28
AU2023210650A1 (en) 2023-08-24
TR201908296T4 (tr) 2019-06-21
KR102537018B1 (ko) 2023-05-30
PL3209302T3 (pl) 2019-10-31
NL301224I1 (no) 2023-03-29
WO2016065019A1 (en) 2016-04-28
US20160362431A1 (en) 2016-12-15
CN111362980A (zh) 2020-07-03
PT3209302T (pt) 2019-07-19
US10730895B2 (en) 2020-08-04
PH12017500746A1 (en) 2017-10-30
JP2017537066A (ja) 2017-12-14
BR112017008198A2 (pt) 2017-12-26
FR23C1035I1 (fr) 2023-12-08
US20200262852A1 (en) 2020-08-20
TW202131931A (zh) 2021-09-01
RU2017117413A3 (no) 2019-05-30
AU2021201414B2 (en) 2023-05-11
PH12017500746B1 (en) 2017-10-30
HUE044115T2 (hu) 2019-10-28
JP6750076B2 (ja) 2020-09-02
TWI718999B (zh) 2021-02-21
US20220153765A1 (en) 2022-05-19
ES2739536T3 (es) 2020-01-31
JP2019218356A (ja) 2019-12-26
US20190375770A1 (en) 2019-12-12
BR112017008198B1 (pt) 2021-02-09
IL276493A (en) 2020-09-30
TW201630924A (zh) 2016-09-01
RS58972B1 (sr) 2019-08-30
AR102389A1 (es) 2017-02-22
TWI755257B (zh) 2022-02-11
EP3209302B1 (en) 2019-04-24
SG11201703170RA (en) 2017-05-30
SI3209302T1 (sl) 2019-06-28
AU2015335941B2 (en) 2021-04-01
US20230106081A1 (en) 2023-04-06
RU2017117413A (ru) 2018-11-26
EP3569587A1 (en) 2019-11-20
UA120437C2 (uk) 2019-12-10
CN111454290B (zh) 2022-12-23
US11091507B2 (en) 2021-08-17
US9446059B2 (en) 2016-09-20
IL268885A (en) 2019-10-31
EP4186510A1 (en) 2023-05-31
CN111362980B (zh) 2022-10-18
JP2023174770A (ja) 2023-12-08
NL301224I2 (nl) 2023-08-16
JP2021183628A (ja) 2021-12-02
DK3209302T3 (da) 2019-05-13
JP2020189864A (ja) 2020-11-26
IL251829B (en) 2019-09-26
US20180079762A1 (en) 2018-03-22
MY189519A (en) 2022-02-16
RU2743347C2 (ru) 2021-02-17
MX2021003840A (es) 2022-06-30
SA521421115B1 (ar) 2022-03-01
CN107206013A (zh) 2017-09-26
AU2021201414A1 (en) 2021-03-25
HUS2300009I1 (hu) 2023-03-28
CN111494395A (zh) 2020-08-07
US10174061B2 (en) 2019-01-08
ZA201702760B (en) 2022-05-25
EP3209302A1 (en) 2017-08-30

Similar Documents

Publication Publication Date Title
NO2023013I1 (no) Combination of foslevodopa and foscarbidopa, each in all forms protected by the basic patent
DK3209778T3 (da) Kombination
DK3152607T3 (da) En antiresonant hulkernefiber
DK3587417T3 (da) 1,3-thiazol-2-yl-substituerede benzamider
DK3154594T3 (da) Fap-aktiverede, terapeutiske midler og anvendelser i forbindelser dermed
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
DK3137168T3 (da) Substituerede 4-phenylpiperidiner, deres fremstilling og anvendelse
DK3174483T3 (da) Hyporørkonstruktion
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
NO3050465T3 (no) Seating
DE112016001950A5 (de) Sitzgruppe
FI11525U1 (fi) Suojausjärjestely
ITUB20152292A1 (it) Accorgimenti per incastonare pietre e solitari.
BR112016030599A2 (pt) novos derivados de aminoalquilbenzotiazepina e suas utilizações
UA32568S (uk) Крісло-гойдалка
FI11484U1 (fi) Suojausjärjestely
ITUB20152120A1 (it) Rimedio naturale, efficace e polivalente
UA31285S (uk) Стілець
UA30915S (uk) Стілець
UA30830S (uk) Стілець
TH160228B (th) เก้าอี้
CL2015000667S1 (es) Machacadora.
ES1112405Y (es) Mosquetón
TH1601000631A (th) อนุพันธ์ไดอะซาคาร์บาโซลในรูป tau-pet-ลิแกนด์
UA26900S (uk) Крісло-гойдалка